
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte Inc. has demonstrated a strong upward trajectory in profitability metrics, with management raising its adjusted EBITDA margin guidance for 2025 to approximately 22.5%, an increase of 190 basis points from the 2024 forecast. The company has also reported a significant year-over-year improvement in its non-GAAP operating margin, which increased by 590 basis points to reach 19.3%. Additionally, the adjusted EBITDA margin for the prior year stood at 21.6%, reflecting an impressive year-over-year growth of 670 basis points, indicating robust operational efficiency and financial health.
Bears say
Veracyte Inc faces significant challenges, as there are critical concerns regarding weaker-than-expected sales from its key diagnostic tests, Decipher and Afirma, which are critical to its revenue streams. Additionally, the company is reporting deteriorating financial metrics, with the estimated revenue per test declining by approximately 4% year-over-year, indicating potential difficulties in maintaining profitability. Furthermore, concerns about operating margins and free cash flow positions may further exacerbate the company's financial outlook and overall market stability.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares